News | July 20, 2010

New CT Technology Reduces Radiation Dose for CTA Scans

July 20, 2010 – New dual source CT technology allows a radiation dose of as low as one millisievert (mSv) for computed tomography angiography (CTA) scans, Siemens announced last week at the 2010 Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (SCCT) in Las Vegas. At SCCT, Somatom Definition Flash CT scanner users also showed how they use the system to display the coronary vessels, as well as the aorta, within one scan.

Recently, cardiologists have been using the Somatom Definition Flash to plan the procedure for one of the newest therapy methods for valvular heart disease: transcatheter aortic valve implantation (TAVI). Prior to this minimally invasive intervention, physicians had to examine the heart’s anatomy closely. This demand is also supported by the cardiovascular CT applications of the imaging software syngo.via. With automated processes, these applications can spare the cardiologists many manual steps that before were necessary – for instance, to measure the vessels.

“Somatom Definition Flash enables us to significantly reduce CTA radiation dose in clinical routine into the sub-mSv range for the vast majority of patients,” said Jörg Hausleiter, M.D., cardiologist and director of the intensive care unit at the German Heart Center in Munich, Germany.

Hausleiter and his colleagues have examined 60 to 70 percent of their patients with a radiation dose below one mSv. The Siemens scanner enables them to display the entire heart volume within only one heartbeat – independent of the patient’s heart rate. This is an improvement in CTA of the coronary vessels, where, until now, conventional technology has required considerably higher dose rates, and examinations in the sub-mSv range were only possible in very few patients. Dual Source CT allows scanning of every patient with high or irregular heart rates even without the use of beta blockers to slow down the heart rate. This means that even patients who cannot tolerate beta blockers may be spared referral to invasive angiography.

Somatom Definition Flash’s low-dose scanning potential also benefits patients with heart valve disease who were selected for a TAVI and must be examined by CT in order to plan the procedure. The minimally invasive TAVI treatment is particularly appropriate for older patients with a high perioperative risk during heart surgery. It links the implantation of an artificial heart valve with a balloon dilatation in the catheter laboratory. The great advantage is that the patient’s thorax must not be opened as the new valve is inserted through the femoral artery or through a small incision between the ribs.

For the preparation of this procedure, Somatom Definition Flash brings even more benefits to the user. TAVI patients are usually multimorbid and suffer from renal insufficiency. They can barely metabolize larger quantities of contrast agent that often have to be applied for a CTA to display the coronary arteries and the aorta.

“For us, Somatom Definition Flash is the best solution to plan a TAVI because it allows us to reduce contrast agent significantly,” said Tobias Pflederer, M.D., cardiologist at University Hospital Erlangen, Germany. “Single-source CTs, for example, require 100 or even 150 milliliters of contrast agent for assessing the abdominal aorta. With the Definition Flash, we need only 40 milliliters for the aorta and the coronary arteries.”

Prior to the TAVI treatment, the cardiologists need to clarify many anatomical issues regarding the vessels. They must know, for example, whether there are stenoses in the peripheral arteries. In that case, they could not insert the new valve through the femoral artery. Furthermore, they must determine the diameter of the aortic bulbus (initial part of the aorta) to select the right size of the artificial valve. syngo.via combines the application modules syngo.CT Vascular Analysis and syngo.CT Cardiac Function to display a dedicated TAVI planning workflow that helps physicians answer all these questions quickly and easily. The software, for instance, automatically exposes the aorta and its valves virtually. It reconstructs the vessel in the most important planes and automatically indicates the measurements that the physician has to conduct for his diagnosis.

For more information: www.siemens.com/healthcare

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init